This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genentech Studies How Alzheimer's Attacks Brain

The discovery of a link between death receptor 6 and APP is important because it suggests that Alzheimer's may be caused when the normal self-destruction mechanism of excess nerve cells in embryos is somehow hijacked or turned back on in adults, says Tessier-Lavigne.

"If the theory is correct, we may be able to attack Alzheimer's in a new way with drugs that can block this biochemical pathway," he adds.

The new discovery published Wednesday by Genentech researchers is just a start. The company has a long way to go before this new theory on the cause of Alzheimer's can be proven, and even longer before new drugs are developed that may be effective against the disease.

Still, the Genentech research adds to the body of knowledge about the possible causes of Alzheimer's. Much of the ongoing work in the field is being directed at developing drugs that can break down toxic beta amyloid in the brain.

So far, however, that work hasn't produced much in the way of positive results. Drugs from Myriad Genetics (MYGN - Get Report) and Neurochem have failed, while another drug from Elan (ELN) and Wyeth (WYE) has produced only lackluster results so far in mid-stage studies. Pfizer, Transition Therapeutics (TTHI) and Eli Lilly (LLY - Get Report) also have so-called "beta-amyloid drugs" under development.

"We still don't understand the relative contribution our new discovery plays in Alzheimer's compared to other mechanisms such as beta amyloid," says Tessier-Lavigne, adding that more research needs to be done to see if there are ways in which they might be complementary.

Meantime, Genentech also is moving ahead on multiple fronts in Alzheimer's drug research. The company bought rights to a beta amyloid drug from privately held Swiss company AC Immune. That drug is currently in a phase I study, but Genentech hasn't disclosed when the study is expected to be completed.

Genentech shares closed up $1.70, or 2%, to $84.70 on Wednesday.
At the time of publication, Feuerstein's Biotech Select model portfolio was long Genentech.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
LLY $74.94 0.09%
MYGN $34.02 0.24%
PFE $33.61 0.63%
ELN $0.00 0.00%
TSLA $212.22 -4.60%


Chart of I:DJI
DOW 17,641.98 -9.28 -0.05%
S&P 500 2,049.49 -1.63 -0.08%
NASDAQ 4,721.0070 -4.6320 -0.10%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs